Matthew E. Ros is recorded as COO at Verastem, Inc. (VSTM) since January 14, 2025. Verastem, Inc. reported in an 8-K filed December 19, 2025 that Matthew E. Ros resigned as Chief Operating Officer, effective December 19, 2025. Verastem, Inc. reported in an 8-K filed January 21, 2025 that Matthew E. Ros was appointed Chief Operating Officer, effective January 14, 2025. Matthew E. Ros has spoken on 1 earnings call across 1 company, most recently for Verastem, Inc. on November 4, 2025. Verastem, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Verastem, Inc. includes Brian M. Stuglik (CEO), Daniel Paterson (CEO and Board Member), Michael Bailey (CEO) and 7 others.
“As previously disclosed on December 15, 2025, as of December 19, 2025, Matthew Ros separated from Verastem, Inc. (the "Company") as its Chief Operating Officer.”
Verastem, Inc. Form 8-K, filed December 19, 2025
· Read the filing
“Effective January 14, 2025, Verastem, Inc. (the “Company”) appointed Matthew E. Ros as Chief Operating Officer of the Company.”
Verastem, Inc. Form 8-K, filed January 21, 2025
· Read the filing
Matthew E. Ros on recent calls
“The strong F-MAP defects and Jacopac growth reflects the high unmet medical need and physician enthusiasm for this first-ever treatment option. The team has achieved significant results since our May approval, and we continue to execute well against all three strategic launch imperatives.”
